Molnupiravir

With $640M in sales of Lagevrio, Merck bumps up revenue forecast

Merck's COVID antiviral treatment Lagevrio racked up sales of $640 million last quarter, shocking analysts who figured it would generate $120 million.

Kevin Dunleavy Oct 26, 2023 10:55am

Merck's Lagevrio to be sold commercially in November, HHS says

Oct 5, 2023 10:35am

Merck's Lagevrio may have triggered new COVID variants: study

Sep 26, 2023 9:35am

Europe's CHMP advises against authorization of Merck's Lagevrio

Feb 24, 2023 10:48am

Slump of Merck's COVID-19 pill continues with trial failure

Feb 21, 2023 10:53am

Merck doesn't expect immediate boost from Keytruda's last nod: CEO

Feb 2, 2023 11:24am